Short Interest in Aptorum Group Limited (NASDAQ:APM) Drops By 59.1%

Aptorum Group Limited (NASDAQ:APM) was the target of a significant decline in short interest in December. As of December 15th, there was short interest totaling 10,748 shares, a decline of 59.1% from the November 30th total of 26,279 shares. Based on an average trading volume of 42,165 shares, the short-interest ratio is currently 0.3 days. Currently, 0.5% of the shares of the stock are short sold. Currently, 0.5% of the shares of the stock are short sold. Based on an average trading volume of 42,165 shares, the short-interest ratio is currently 0.3 days.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Aptorum Group in a research note on Monday, December 22nd. Wall Street Zen raised shares of Aptorum Group from a “sell” rating to a “hold” rating in a research report on Saturday, October 11th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has a consensus rating of “Sell”.

Aptorum Group Price Performance

Shares of NASDAQ APM traded down $0.03 during mid-day trading on Friday, hitting $1.14. The stock had a trading volume of 21,411 shares, compared to its average volume of 48,625. The company has a 50 day moving average of $1.36 and a two-hundred day moving average of $1.51. Aptorum Group has a twelve month low of $0.69 and a twelve month high of $7.49.

Aptorum Group Company Profile

Aptorum Group Ltd. (NASDAQ: APM) is a global biopharmaceutical company incorporated under the laws of the Cayman Islands and headquartered in Hong Kong. Since its Nasdaq listing in 2018, the company has focused on the discovery, development and commercialization of novel therapeutics and diagnostic products. Aptorum’s research efforts are aimed at addressing unmet medical needs across oncology, metabolic disorders, infectious diseases and neurological conditions.

The company’s diversified pipeline includes both small-molecule and biologic drug candidates, as well as companion diagnostic tools.